MCID: LCL006
MIFTS: 64

Localized Scleroderma

Categories: Rare diseases, Skin diseases, Immune diseases, Neuronal diseases, Nephrological diseases, Respiratory diseases, Bone diseases, Genetic diseases

Aliases & Classifications for Localized Scleroderma

MalaCards integrated aliases for Localized Scleroderma:

Name: Localized Scleroderma 12 53 59 37 15 73
Morphea 12 53 55 73
Localized Fibrosing Scleroderma 53 59
Scleroderma, Circumscribed or Localized 12
Circumscribed Scleroderma 12
Scleroderma, Localized 53
Localised Morphoea 12
Localized Morphea 12

Characteristics:

Orphanet epidemiological data:

59
localized scleroderma
Inheritance: Not applicable; Prevalence: 1-9/100000 (Europe); Age of onset: All ages; Age of death: normal life expectancy;

Classifications:

Orphanet: 59  
Rare skin diseases


External Ids:

Disease Ontology 12 DOID:8472
ICD10 33 L94.0
ICD9CM 35 701.0
MeSH 44 D012594
NCIt 50 C72069
Orphanet 59 ORPHA90289
UMLS via Orphanet 74 C0036420
ICD10 via Orphanet 34 L94.0
MESH via Orphanet 45 D012594
KEGG 37 H01493

Summaries for Localized Scleroderma

NIH Rare Diseases : 53 Localized scleroderma is characterized by thickening of the skin from excessive collagen deposits. Collagen is a protein normally present in our skin that provides structural support. However, when too much collagen is made, the skin becomes stiff and hard. Localized types of scleroderma are those limited to the skin and related tissues and, in some cases, the muscle below. Internal organs are not affected by localized scleroderma, and localized scleroderma can never progress to the systemic form of the disease. Often, localized conditions improve or go away on their own over time, but the skin changes and damage that occur when the disease is active can be permanent. For some people, localized scleroderma is serious and disabling. There are two generally recognized types of localized scleroderma: morphea and linear.  

MalaCards based summary : Localized Scleroderma, also known as morphea, is related to systemic scleroderma and keloids, and has symptoms including exanthema and pruritus. An important gene associated with Localized Scleroderma is MMP1 (Matrix Metallopeptidase 1), and among its related pathways/superpathways are GPCR Pathway and TGF-Beta Pathway. The drugs Vaccines and Lidocaine have been mentioned in the context of this disorder. Affiliated tissues include skin, lung and bone, and related phenotypes are hyperpigmentation of the skin and hypopigmentation of the skin

Wikipedia : 76 Morphea, also called localized scleroderma or circumscribed scleroderma, is a form of scleroderma that... more...

Related Diseases for Localized Scleroderma

Diseases in the Systemic Scleroderma family:

Scleroderma, Familial Progressive Localized Scleroderma

Diseases related to Localized Scleroderma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 187)
# Related Disease Score Top Affiliating Genes
1 systemic scleroderma 32.1 CTGF SELE TGFB1
2 keloids 30.2 MMP1 SMAD3 TGFB1
3 central nervous system vasculitis 30.0 IL6 TNF
4 arthritis 29.1 IL6 MMP1 MMP13 TNF
5 rheumatoid arthritis 27.0 IL6 MMP1 MMP13 SELE TGFB1 TNF
6 linear scleroderma 11.4
7 atrophoderma of pierini and pasini 11.1
8 fibromatosis, gingival, 1 10.8 MMP1 TGFB1
9 tendinopathy 10.8 DCN MMP1
10 periodontitis, chronic 10.7 IL6 MMP1
11 diabetic foot ulcers 10.7 IL6 TGFB1
12 kidney hypertrophy 10.6 CTGF TGFB1
13 cholecystolithiasis 10.6 CTGF TGFB1
14 stiff skin syndrome 10.6 CTGF TGFB1
15 beryllium disease 10.6 TGFB1 TNF
16 preterm premature rupture of the membranes 10.6 IL6 MMP1
17 scorpion envenomation 10.6 IL6 TNF
18 leukomalacia 10.6 IL6 TNF
19 angioimmunoblastic lymphadenopathy with dysproteinemia 10.5 IL6 TNF
20 odontogenic myxoma 10.5 DCN MMP1
21 streptococcal toxic-shock syndrome 10.5 IL6 TNF
22 null-cell leukemia 10.5 IL6 TNF
23 retinitis pigmentosa 55 10.5 IL6 TNF
24 clonorchiasis 10.5 TGFB1 TNF
25 hypertrophic scars 10.5 SMAD3 TGFB1
26 anca-associated vasculitis 10.5 IL6 TNF
27 acute vascular insufficiency of intestine 10.5 IL6 TNF
28 poems syndrome 10.5 IL6 TNF
29 microscopic colitis 10.4 IL6 TNF
30 meconium aspiration syndrome 10.4 IL6 TNF
31 burning mouth syndrome 10.4 IL6 TNF
32 osteosclerotic myeloma 10.4 IL6 TNF
33 stachybotrys chartarum 10.4 IL6 TNF
34 louse-borne relapsing fever 10.4 IL6 TNF
35 penile disease 10.4 DCN SMAD3 TGFB1
36 peyronie's disease 10.4 DCN SMAD3 TGFB1
37 listeriosis 10.3 IL6 TNF
38 gingival fibromatosis 10.3 CTGF MMP1 TGFB1
39 dupuytren contracture 10.3 DCN TGFB1
40 trachoma 10.3 CTGF TNF
41 transverse myelitis 10.3 IL6 TNF
42 carpal tunnel syndrome 10.3 CTGF IL6 TGFB1
43 pulpitis 10.3 IL6 MMP1 TNF
44 ureteral disease 10.3 CTGF SMAD3 TGFB1
45 lymph node disease 10.3 IL6 MMP1 TNF
46 laryngitis 10.3 IL6 TGFB1 TNF
47 posterior urethral valves 10.3 IL6 TGFB1 TNF
48 ischemic heart disease 10.3 IL6 TNF
49 urinary tract obstruction 10.2 CTGF SMAD3 TGFB1
50 idiopathic neutropenia 10.2 IL6 TGFB1 TNF

Comorbidity relations with Localized Scleroderma via Phenotypic Disease Network (PDN):


Systemic Scleroderma Vulva Cancer

Graphical network of the top 20 diseases related to Localized Scleroderma:



Diseases related to Localized Scleroderma

Symptoms & Phenotypes for Localized Scleroderma

Human phenotypes related to Localized Scleroderma:

59 32 (show all 16)
# Description HPO Frequency Orphanet Frequency HPO Source Accession
1 hyperpigmentation of the skin 59 32 hallmark (90%) Very frequent (99-80%) HP:0000953
2 hypopigmentation of the skin 59 32 hallmark (90%) Very frequent (99-80%) HP:0001010
3 cigarette-paper scars 59 32 hallmark (90%) Very frequent (99-80%) HP:0001073
4 split hand 59 32 occasional (7.5%) Occasional (29-5%) HP:0001171
5 arthralgia 59 32 occasional (7.5%) Occasional (29-5%) HP:0002829
6 skeletal muscle atrophy 59 32 frequent (33%) Frequent (79-30%) HP:0003202
7 scarring alopecia of scalp 59 32 occasional (7.5%) Occasional (29-5%) HP:0004552
8 flexion contracture of toe 59 32 occasional (7.5%) Occasional (29-5%) HP:0005830
9 stiff skin 59 32 hallmark (90%) Very frequent (99-80%) HP:0030053
10 hemiatrophy of lower limb 59 32 occasional (7.5%) Occasional (29-5%) HP:0100557
11 hemiatrophy of upper limb 59 32 occasional (7.5%) Occasional (29-5%) HP:0100558
12 lipoatrophy 59 32 occasional (7.5%) Occasional (29-5%) HP:0100578
13 myalgia 59 32 occasional (7.5%) Occasional (29-5%) HP:0003326
14 dermal atrophy 59 Very frequent (99-80%)
15 hemiatrophy 59 Occasional (29-5%)
16 flexion contracture 59 Occasional (29-5%)

UMLS symptoms related to Localized Scleroderma:


exanthema, pruritus

MGI Mouse Phenotypes related to Localized Scleroderma:

46 (show all 13)
# Description MGI Source Accession Score Top Affiliating Genes
1 cardiovascular system MP:0005385 10.13 IL6 ARHGEF1 CTGF MMP13 SELE SMAD3
2 homeostasis/metabolism MP:0005376 10.13 CTGF MMP1 MMP13 DCN SELE IL6
3 cellular MP:0005384 10.11 IL6 CTGF MMP13 DCN SELE TNF
4 growth/size/body region MP:0005378 10.06 IL6 CTGF MMP13 DCN SELE TNF
5 immune system MP:0005387 10.01 ARHGEF1 IL6 MMP1 DCN SELE TNF
6 integument MP:0010771 9.97 CTGF MMP13 DCN SELE IL6 SMAD3
7 digestive/alimentary MP:0005381 9.95 IL6 CTGF DCN TNF SMAD3 TGFB1
8 craniofacial MP:0005382 9.89 CTGF DCN TNF SMAD3 TGFB1
9 liver/biliary system MP:0005370 9.8 IL6 CTGF SELE SMAD3 TGFB1 TNF
10 neoplasm MP:0002006 9.73 MMP1 DCN IL6 SMAD3 TGFB1 TNF
11 respiratory system MP:0005388 9.63 IL6 CTGF DCN SELE TNF TGFB1
12 skeleton MP:0005390 9.5 IL6 CTGF MMP13 DCN TNF SMAD3
13 vision/eye MP:0005391 9.17 CTGF DCN SELE IL6 SMAD3 TGFB1

Drugs & Therapeutics for Localized Scleroderma

Drugs for Localized Scleroderma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 145)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1 Vaccines Phase 4
2
Lidocaine Approved, Vet_approved Phase 2, Phase 3 137-58-6 3676
3
Lenograstim Approved, Investigational Phase 3 135968-09-1
4
Dopamine Approved Phase 3 51-61-6, 62-31-7 681
5
Omeprazole Approved, Investigational, Vet_approved Phase 3 73590-58-6 4594
6
Acetylcholine Approved Phase 3 51-84-3 187
7
Bosentan Approved, Investigational Phase 2, Phase 3 147536-97-8 104865
8
Cyclophosphamide Approved, Investigational Phase 3,Phase 2,Phase 1 50-18-0, 6055-19-2 2907
9
Imiquimod Approved, Investigational Phase 3 99011-02-6 57469
10
Domperidone Approved, Investigational, Vet_approved Phase 3 57808-66-9 3151
11
Tadalafil Approved, Investigational Phase 3 171596-29-5 110635
12
Alginic acid Approved, Investigational Phase 3 9005-32-7
13
Glucosamine Approved, Investigational, Nutraceutical Phase 2, Phase 3 3416-24-8 439213
14
Citric Acid Approved, Nutraceutical, Vet_approved Phase 3 77-92-9 311
15 Antirheumatic Agents Phase 3,Phase 2,Phase 1
16 insulin Phase 3
17 Sildenafil Citrate Phase 3 171599-83-0
18 interferons Phase 3,Phase 1
19 Alkylating Agents Phase 3,Phase 2,Phase 1
20 abobotulinumtoxinA Phase 3
21 Fibrinolytic Agents Phase 2, Phase 3
22 Central Nervous System Depressants Phase 2, Phase 3,Not Applicable
23 Adjuvants, Immunologic Phase 3
24 Chelating Agents Phase 3
25 Cholinergic Agents Phase 3
26 Gastrointestinal Agents Phase 3
27 Sodium Channel Blockers Phase 2, Phase 3
28 Coagulants Phase 3,Phase 1
29 Neuromuscular Agents Phase 3
30 Glucuronyl glucosamine glycan sulfate Phase 2, Phase 3
31 Neurotransmitter Agents Phase 3
32 Hemostatics Phase 3,Phase 1
33 Anesthetics Phase 2, Phase 3,Not Applicable
34 Anesthetics, Local Phase 2, Phase 3
35 onabotulinumtoxinA Phase 3
36 Diuretics, Potassium Sparing Phase 2, Phase 3
37 Antacids Phase 3
38 Dopamine Agents Phase 3
39 Anti-Arrhythmia Agents Phase 2, Phase 3
40 Dopamine Antagonists Phase 3
41 Vasodilator Agents Phase 3,Phase 2
42 Endothelin Receptor Antagonists Phase 2, Phase 3
43 Peripheral Nervous System Agents Phase 2, Phase 3,Phase 3,Phase 1
44 Hypoglycemic Agents Phase 2, Phase 3
45 Hypolipidemic Agents Phase 2, Phase 3
46 Pharmaceutical Solutions Phase 2, Phase 3,Phase 3,Not Applicable
47 Phosphodiesterase 5 Inhibitors Phase 3
48 Phosphodiesterase Inhibitors Phase 3,Phase 2
49 Antihypertensive Agents Phase 2, Phase 3,Phase 1
50 Anticoagulants Phase 2, Phase 3,Phase 3,Phase 1

Interventional clinical trials:

(show top 50) (show all 84)
# Name Status NCT ID Phase Drugs
1 Influenza Vaccination in Patients With Scleroderma Unknown status NCT01002508 Phase 4
2 Efficacy and Safety of PLACENTEX ® i.m. in Patients With Scleroderma Diseases Recruiting NCT03388255 Phase 4 Polydeoxyribonucleotides
3 Imiquimod in Children With Plaque Morphea Completed NCT00147771 Phase 3 Imiquimod 5% cream
4 Sildenafil Effect on Digital Ulcer Healing in sClerodErma SEDUCE STUDY Completed NCT01295736 Phase 3 Sildenafil;placebo
5 Effectiveness and Safety of Lidocaine for Scleroderma Completed NCT00740285 Phase 2, Phase 3 Lidocaine 2% without vessel constrictor
6 High Dose Cyclophosphamide for Treatment of Scleroderma Completed NCT00501995 Phase 3 IV Cyclophosphamide
7 A Randomized Control Trial to Assess the Efficacy of Tadalafil in Raynaud's Phenomenon in Scleroderma Completed NCT01117298 Phase 3 Tadalafil;Placebo
8 Efficacy of Botulinum Toxin In Scleroderma-Associated Raynaud's Syndrome Completed NCT02165111 Phase 3 Onabotulinumtoxin A;sterile saline solution
9 Gastroesophageal Reflux Treatment in Scleroderma Completed NCT01878526 Phase 3 Alginic acid;placebo (for domperidone);Domperidone;placebo (of alginic acid)
10 Efficacy and Safety of Oral Bosentan in Pulmonary Fibrosis Associated With Scleroderma Completed NCT00070590 Phase 2, Phase 3 Bosentan
11 Effect of Sildenafil on the Microcirculatory Blood Flow and Endothelial Progenitor Cells in Systemic Sclerosis Completed NCT01347008 Phase 3 Sildenafil citrate;Placebo (Sugar pill)
12 Scleroderma Lung Disease Completed NCT00004563 Phase 3 Cyclophosphamide;Placebo
13 Imiquimod 5% Cream in Plaque-type Morphea: A Pilot, Prospective Open-label Study Withdrawn NCT00230373 Phase 3 imiquimod 5% cream (Aldara)
14 A Protocol Based Treatment for Debilitating Fibrosing Skin Disorders With (Anti-CD 20), Rituximab, Evaluating Safety and Efficacy Unknown status NCT00936546 Phase 2 Rituximab
15 Efficacy and Safety of Imatinib in Scleroderma Completed NCT00479934 Phase 2 imatinib mesylate
16 Ultraviolet B (UVB) Light Therapy in the Treatment of Skin Conditions With Altered Dermal Matrix Completed NCT00129428 Phase 1, Phase 2
17 Effect of Bosentan in Scleroderma Renal Crisis Completed NCT01241383 Phase 2 Bosentan
18 Digital Ischemic Lesions in Scleroderma Treated With Oral Treprostinil Diethanolamine Completed NCT00775463 Phase 2 treprostinil diethanolamine;placebo
19 Safety Evaluation of Dasatinib in Subjects With Scleroderma Pulmonary Fibrosis Completed NCT00764309 Phase 1, Phase 2 dasatinib
20 Cyclophosphamide and rATG With Hematopoietic Stem Cell Support in Systemic Scleroderma Completed NCT00278525 Phase 2 standard of care
21 IL1-TRAP, Rilonacept, in Systemic Sclerosis Completed NCT01538719 Phase 1, Phase 2 Rilonacept
22 A Study to Evaluate the Safety and Efficacy of Abatacept in Patients With Diffuse Systemic Sclerosis (Scleroderma) Completed NCT00442611 Phase 1, Phase 2 Abatacept;Placebo
23 Oral Type I Collagen for Relieving Scleroderma Completed NCT00005675 Phase 2 Oral bovine type I collagen;Placebo
24 Diltiazem Gel Versus Nitroglycerin Ointment in Healing Process of Scleroderma Digital Ulcers Completed NCT02801305 Phase 2 Diltiazem Gel 2%;Nitroglycerin Ointment 2%;Vaseline
25 Zibotentan Better Renal Scleroderma Outcome Study Completed NCT02047708 Phase 2 Zibotentan
26 Comparison of Therapeutic Regimens for Scleroderma Interstitial Lung Disease (The Scleroderma Lung Study II) Completed NCT00883129 Phase 2 Mycophenolate mofetil;Cyclophosphamide;Placebo
27 Psychological Treatments for Scleroderma Completed NCT00007267 Phase 2
28 Study of Pomalidomide (CC-4047) to Evaluate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Effectiveness for Subjects With Systemic Sclerosis With Interstitial Lung Disease Completed NCT01559129 Phase 2 Pomalidomide (CC-4047);Placebo
29 Pirfenidone Plus M-DDO Gel in Moderate and Severe Acne Recruiting NCT03076320 Phase 1, Phase 2
30 Atorvastatin for Microvascular Endothelial Function and Raynaud in Early Diffuse Scleroderma Recruiting NCT02370784 Phase 2 atorvastatin;Placebo
31 Treatment of Refractory Sever Systemic Scleroderma by Injection of Allogeneic Mesenchymal Stem Cells Recruiting NCT02213705 Phase 1, Phase 2
32 Scleroderma Lung Study III - Combining Pirfenidone With Mycophenolate Recruiting NCT03221257 Phase 2 Pirfenidone (PFD);Placebo (Plac);Mycophenolate Mofetil (MMF)
33 Oral Ifetroban to Treat Diffuse Cutaneous Systemic Sclerosis (SSc) or SSc-associated Pulmonary Arterial Hypertension Recruiting NCT02682511 Phase 2 Oral Ifetroban;Oral Placebo
34 Riociguat in Scleroderma Associated Digital Ulcers Active, not recruiting NCT02915835 Phase 2 Riociguat;Placebo
35 Pilot Study Evaluating the Efficacy of a Topical PDE4 Inhibitor for Morphea Not yet recruiting NCT03351114 Phase 2 Crisaborole
36 Proof of Concept Trial of Gleevec (Imatinib) in Active Diffuse Scleroderma Terminated NCT01545427 Phase 2 Imatinib mesylate
37 Placebo Controlled Trial of Bosentan in Scleroderma Patients Terminated NCT00377455 Phase 2 Bosentan;Placebo
38 A Study of the Safety and Tolerability of MEDI-551 in Scleroderma Completed NCT00946699 Phase 1
39 A Study to Evaluate Safety and Tolerability of Multiple Doses of MEDI-546 in Adult Subjects With Scleroderma Completed NCT00930683 Phase 1 MEDI-546;MEDI-546;MEDI-546;MEDI-546;MEDI-546;MEDI-546;MEDI-546;MEDI-546;MEDI-546
40 Safety & Suitability of Dabigatran to Inhibit Thrombin in Scleroderma Active, not recruiting NCT02426229 Phase 1 dabigatran etexilate
41 Safety and Value of Self Bone Marrow Transplants Following Chemotherapy in Scleroderma Patients Terminated NCT00040651 Phase 1 Fludarabine;Cyclophosphamide;Thymoglobulin
42 Comparative Effectiveness Trial in the Treatment of Pediatric Plaque Morphea Withdrawn NCT02680717 Phase 1 Clobetasol;Calcipotriene;Tacrolimus
43 Fractional Carbon Dioxide Laser Versus UVA 1 in Treatment of Localized Scleroderma Unknown status NCT02002897 Not Applicable
44 Genetic Variants in Linear Localized Scleroderma Unknown status NCT02222038 Not Applicable
45 Treatment Study Comparing UVA-1 Phototherapy Versus Placebo Treatment for Morphea Unknown status NCT01799174 Not Applicable
46 Empirical Comparative Study of Variation Blood Level Antibody Vitamin D at Scleroderma (SSc) Patients Compared Healthy Peoples Unknown status NCT01553890 Not Applicable
47 Obstructive Sleep Apnea in Scleroderma and Pulmonary Involvement Unknown status NCT02740569
48 Treatment Study Comparing Medium or High Dose Uva-1 Treatment 3x/Week Versus Fluocinonide 0.05% Cream in the Treatment of Morphea. Completed NCT00812188 Not Applicable
49 The CARRA Registry Completed NCT01697254
50 UVA1 Light for Treatment of Scleroderma and Similar Conditions Completed NCT00476801 Not Applicable

Search NIH Clinical Center for Localized Scleroderma

Genetic Tests for Localized Scleroderma

Anatomical Context for Localized Scleroderma

MalaCards organs/tissues related to Localized Scleroderma:

41
Skin, Lung, Bone, Endothelial, Bone Marrow, Skeletal Muscle, Testes

Publications for Localized Scleroderma

Articles related to Localized Scleroderma:

(show top 50) (show all 392)
# Title Authors Year
1
Collagen-enriched serpiginous skin lesion in a cat resembling the linear form of localized scleroderma in humans. ( 29794370 )
2018
2
Impact of a new simplified disability scoring system for adult patients with localized scleroderma. ( 29369402 )
2018
3
Development of minimum standards of care for juvenile localized scleroderma. ( 29728839 )
2018
4
Diagnostic criteria, severity classification and guidelines of localized scleroderma. ( 29687475 )
2018
5
Supportive Use of Adipose-Derived Stem Cells in Cell-Assisted Lipotransfer for Localized Scleroderma. ( 29794702 )
2018
6
Tocilizumab as a potential therapeutic option for children with severe, refractory juvenile localized scleroderma. ( 29077971 )
2018
7
Detection of autoimmune antibodies in localized scleroderma by synthetic oligonucleotide antigens. ( 29641558 )
2018
8
Abatacept Improves Skin-score and Reduces Lesions in Patients with Localized Scleroderma: A Case Series. ( 29313055 )
2018
9
Disease course and long-term outcome of juvenile localized scleroderma: Experience from a single pediatric rheumatology Centre and literature review. ( 29729451 )
2018
10
Localized scleroderma occurring after treatment of chronic hepatitis C with sofosbuvir and ribavirin. ( 29863777 )
2018
11
Comparing ultraviolet light A photo(chemo)therapy with Methotrexate protocol in childhood localized scleroderma: Evidence from systematic review and meta-analysis approach. ( 29655520 )
2018
12
From Localized Scleroderma to Systemic Sclerosis: Coexistence or Possible Evolution. ( 29666638 )
2018
13
Reliability of LoSCAT score for activity and tissue damage assessment in a large cohort of patients with Juvenile Localized Scleroderma. ( 29914516 )
2018
14
Localized Scleroderma of the Head and Face Area: A Retrospective Cross-sectional Study of 96 Patients from 5 German Tertiary Referral Centres. ( 29507998 )
2018
15
Juvenile Localized Scleroderma with Hyaline Deposits in the Renal Arteriole. ( 29805370 )
2018
16
Esophageal abnormalities in juvenile localized scleroderma: is it associated with other extracutaneous manifestations? ( 29173689 )
2017
17
Musculoskeletal MRI findings of juvenile localized scleroderma. ( 28091699 )
2017
18
Anti-dense Fine Speckled 70 Autoantibodies in Japanese Children with Dermatomyositis, Localized Scleroderma, and Idiopathic Arthritis with Iridocyclitis. ( 28461535 )
2017
19
The role of local temperature and other clinical characteristics of localized scleroderma as markers of disease activity. ( 27943304 )
2017
20
Surgical Management of Localized Scleroderma. ( 29090197 )
2017
21
Localized Scleroderma, Systemic Sclerosis and Cardiovascular Risk: A Danish Nationwide Cohort Study. ( 29136260 )
2017
22
Thrombocytopenia Associated with Localized Scleroderma: Report of Four Pediatric Cases and Review of the Literature. ( 28543515 )
2017
23
Quantitative Assessment of Skin Stiffness in Localized Scleroderma Using Ultrasound Shear-Wave Elastography. ( 28457631 )
2017
24
Periostin in Mature Stage Localized Scleroderma. ( 28566901 )
2017
25
Localized scleroderma: clinical and epidemiological features with emphasis on adulthood- versus childhood-onset disease differences. ( 28271552 )
2017
26
European Dermatology Forum S1-guideline on the diagnosis and treatment of sclerosing diseases of the skin, Part 1: localized scleroderma, systemic sclerosis and overlap syndromes. ( 28792092 )
2017
27
Systemic sclerosis complicated with localized scleroderma-like lesions induced by KAPbner phenomenon. ( 29279288 )
2017
28
Evaluation of mean platelet volume in localized scleroderma. ( 29166498 )
2017
29
Neurological abnormalities in localized scleroderma of the face and head: a case series study for evaluation of imaging findings and clinical course. ( 27700194 )
2016
30
A systematic review of tools for determining activity of localized scleroderma in paediatric and adult patients. ( 27401109 )
2016
31
Fractional carbon dioxide laser versus low-dose UVA-1 phototherapy for treatment of localized scleroderma:A a clinical and immunohistochemical randomized controlled study. ( 27510285 )
2016
32
Lichen sclerosus associated with localized scleroderma: dermoscopy contribution. ( 27579757 )
2016
33
Predictors of Longitudinal Quality of Life in Pediatric Localized Scleroderma. ( 27696700 )
2016
34
Esophageal abnormalities in juvenile localized scleroderma: is it associated with other extracutaneous manifestations? ( 27693175 )
2016
35
Lupus erythematosus and localized scleroderma coexistent at the same sites: a rare presentation of overlap syndrome of connective-tissue diseases. ( 27274545 )
2016
36
German guidelines for the diagnosis and therapy of localized scleroderma. ( 26819124 )
2016
37
Localized Scleroderma: A Clinical Review. ( 27604889 )
2016
38
Mild Cognitive Impairment as a single sign of brain hemiatrophy in patient with Localized Scleroderma and Parry-Romberg Syndrome. ( 27154452 )
2016
39
Is Localized Scleroderma Caused by Borrelia burgdorferi? ( 27387068 )
2016
40
Evaluation of serum concentrations of the selected cytokines in patients with localized scleroderma. ( 26985179 )
2016
41
BILATERAL CHOROIDAL EXCAVATION IN JUVENILE LOCALIZED SCLERODERMA. ( 27533641 )
2016
42
Measurement of transepidermal water loss in localized scleroderma. ( 26970329 )
2016
43
Use of Mycophenolate Mofetil in Patients with Severe Localized Scleroderma Resistant or Intolerant to Methotrexate. ( 26582717 )
2016
44
Correlation of clinical tools to determine activity of localized scleroderma in paediatric patients. ( 26138783 )
2016
45
Localized scleroderma en coup de sabre in the Neurology Clinic. ( 27456882 )
2016
46
Drug Survival and Predictors of Drug Survival for Methotrexate Treatment in a Retrospective Cohort of Adult Patients with Localized Scleroderma. ( 26983450 )
2016
47
Oxidative stress parameters in localized scleroderma patients. ( 27591994 )
2016
48
Systemic sclerosis and localized scleroderma--current concepts and novel targets for therapy. ( 26577237 )
2016
49
Localized Scleroderma Presenting as Port-wine Stains: Report of Two Cases and a Literature Review. ( 25791763 )
2015
50
Durometry as an Outcome Measure in Juvenile Localized Scleroderma. ( 26302039 )
2015

Variations for Localized Scleroderma

Expression for Localized Scleroderma

Search GEO for disease gene expression data for Localized Scleroderma.

Pathways for Localized Scleroderma

Pathways related to Localized Scleroderma according to GeneCards Suite gene sharing:

(show top 50) (show all 55)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.58 ARHGEF1 CTGF IL6 MMP1 MMP13 SMAD3
2
Show member pathways
13.37 ARHGEF1 CTGF IL6 SMAD3 TGFB1 TNF
3
Show member pathways
13.18 CTGF IL6 SMAD3 TGFB1 TNF
4 12.7 ARHGEF1 IL6 MMP1 SMAD3 TGFB1
5
Show member pathways
12.64 DCN MMP1 MMP13 TGFB1
6
Show member pathways
12.59 CTGF IL6 TGFB1 TNF
7
Show member pathways
12.46 IL6 SMAD3 TGFB1 TNF
8
Show member pathways
12.33 IL6 SMAD3 TGFB1 TNF
9 12.31 IL6 SMAD3 TGFB1 TNF
10
Show member pathways
12.22 IL6 MMP1 MMP13 TNF
11 12.17 ARHGEF1 DCN TGFB1 TNF
12 12.15 CTGF SMAD3 TGFB1
13
Show member pathways
12.14 MMP1 SELE TGFB1
14 12.14 IL6 TGFB1 TNF
15
Show member pathways
12.12 IL6 TGFB1 TNF
16
Show member pathways
12.12 IL6 SMAD3 TGFB1 TNF
17 12.08 IL6 SMAD3 TGFB1
18 12.06 CTGF SMAD3 TGFB1
19
Show member pathways
12.03 IL6 SMAD3 TGFB1
20
Show member pathways
12 IL6 SMAD3 TGFB1
21 11.98 MMP1 SMAD3 TGFB1
22
Show member pathways
11.97 CTGF IL6 SMAD3 TGFB1
23 11.92 IL6 TGFB1 TNF
24 11.9 IL6 SMAD3 TGFB1 TNF
25 11.86 IL6 SELE TNF
26 11.85 IL6 SMAD3 TGFB1
27
Show member pathways
11.81 MMP1 MMP13 TNF
28 11.81 IL6 MMP1 TGFB1 TNF
29 11.79 IL6 TGFB1 TNF
30
Show member pathways
11.77 IL6 SMAD3 TGFB1
31 11.77 IL6 MMP1 SMAD3 TGFB1 TNF
32 11.71 IL6 MMP1 SELE
33 11.69 IL6 MMP1 TGFB1 TNF
34 11.66 IL6 TGFB1 TNF
35 11.63 DCN SMAD3 TGFB1 TNF
36 11.54 SMAD3 TGFB1 TNF
37 11.47 CTGF IL6 TGFB1 TNF
38 11.46 CTGF SMAD3 TGFB1
39 11.42 CTGF IL6 TNF
40
Show member pathways
11.42 IL6 MMP1 SELE TNF
41
Show member pathways
11.4 SMAD3 TGFB1
42 11.37 IL6 SMAD3 TNF
43 11.27 IL6 MMP1 SMAD3 TGFB1
44 11.24 IL6 SELE TNF
45 11.22 DCN IL6 MMP1
46 11.19 SMAD3 TGFB1
47 11.15 IL6 TGFB1 TNF
48 11.1 CTGF SMAD3
49 11.04 IL6 TNF
50 11.02 IL6 SELE SMAD3 TGFB1 TNF

GO Terms for Localized Scleroderma

Cellular components related to Localized Scleroderma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 9.56 CTGF DCN DEFB1 IL6 MMP1 MMP13
2 extracellular matrix GO:0031012 9.46 DCN MMP1 MMP13 TGFB1
3 Golgi lumen GO:0005796 9.43 DCN DEFB1 TGFB1
4 extracellular space GO:0005615 9.23 CTGF DCN DEFB1 IL6 MMP13 SELE

Biological processes related to Localized Scleroderma according to GeneCards Suite gene sharing:

(show all 38)
# Name GO ID Score Top Affiliating Genes
1 immune response GO:0006955 9.95 DEFB1 IL6 SMAD3 TNF
2 regulation of signaling receptor activity GO:0010469 9.92 CTGF IL6 TGFB1 TNF
3 inflammatory response GO:0006954 9.9 IL6 SELE TGFB1 TNF
4 positive regulation of apoptotic process GO:0043065 9.88 ARHGEF1 IL6 TGFB1 TNF
5 aging GO:0007568 9.83 CTGF DCN TGFB1
6 positive regulation of protein phosphorylation GO:0001934 9.81 CTGF TGFB1 TNF
7 positive regulation of NF-kappaB transcription factor activity GO:0051092 9.79 IL6 TGFB1 TNF
8 leukocyte migration GO:0050900 9.78 MMP1 SELE TGFB1 TNF
9 positive regulation of DNA binding transcription factor activity GO:0051091 9.77 IL6 SMAD3 TNF
10 defense response to Gram-positive bacterium GO:0050830 9.74 DEFB1 IL6 TNF
11 wound healing GO:0042060 9.73 DCN SMAD3 TGFB1
12 positive regulation of gene expression GO:0010628 9.72 CTGF IL6 SMAD3 TGFB1 TNF
13 positive regulation of peptidyl-serine phosphorylation GO:0033138 9.71 IL6 TGFB1 TNF
14 extracellular matrix disassembly GO:0022617 9.69 DCN MMP1 MMP13
15 endoderm development GO:0007492 9.68 SMAD3 TGFB1
16 positive regulation of protein import into nucleus GO:0042307 9.67 SMAD3 TGFB1
17 protein import into nucleus, translocation GO:0000060 9.67 TGFB1 TNF
18 positive regulation of collagen biosynthetic process GO:0032967 9.66 CTGF TGFB1
19 positive regulation of pri-miRNA transcription by RNA polymerase II GO:1902895 9.66 SMAD3 TGFB1
20 positive regulation of protein complex assembly GO:0031334 9.65 TGFB1 TNF
21 cell-cell junction organization GO:0045216 9.64 SMAD3 TGFB1
22 negative regulation of myoblast differentiation GO:0045662 9.64 TGFB1 TNF
23 regulation of transforming growth factor beta receptor signaling pathway GO:0017015 9.63 SMAD3 TGFB1
24 positive regulation of chemokine production GO:0032722 9.62 IL6 TNF
25 leukocyte tethering or rolling GO:0050901 9.61 SELE TNF
26 lens fiber cell differentiation GO:0070306 9.58 SMAD3 TGFB1
27 extrinsic apoptotic signaling pathway GO:0097191 9.58 SMAD3 TGFB1 TNF
28 negative regulation of lipid storage GO:0010888 9.55 IL6 TNF
29 SMAD protein complex assembly GO:0007183 9.52 SMAD3 TGFB1
30 regulation of striated muscle tissue development GO:0016202 9.49 SMAD3 TGFB1
31 positive regulation of extracellular matrix assembly GO:1901203 9.46 SMAD3 TGFB1
32 regulation of binding GO:0051098 9.43 SMAD3 TGFB1
33 negative regulation of mitotic cell cycle GO:0045930 9.43 SMAD3 TGFB1 TNF
34 positive regulation of mononuclear cell migration GO:0071677 9.37 TGFB1 TNF
35 cytokine-mediated signaling pathway GO:0019221 9.35 DCN IL6 MMP1 TGFB1 TNF
36 evasion or tolerance of host defenses by virus GO:0019049 9.16 SMAD3 TGFB1
37 negative regulation of fat cell differentiation GO:0045599 8.92 IL6 SMAD3 TGFB1 TNF
38 positive regulation of transcription by RNA polymerase II GO:0045944 10.06 DCN IL6 SMAD3 TGFB1 TNF

Molecular functions related to Localized Scleroderma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 growth factor activity GO:0008083 9.13 CTGF IL6 TGFB1
2 collagen binding GO:0005518 8.8 DCN MMP13 SMAD3

Sources for Localized Scleroderma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....